20 new stocks make our Dividend Growth Stocks Model Portfolio this month, which was made available to members on February 27, 2020.
Recap from January’s Picks
Our Dividend Growth Stocks Model Portfolio underperformed the S&P 500 from January 29, 2020 through February 25, 2020. The Model Portfolio fell 5.4% on a price return basis and 5.2% on a total return basis. The S&P 500 fell 4.3% on a price return and total return basis. The portfolio’s best performing stock was up 8%. Overall, nine out of the 25 Dividend Growth Stocks outperformed the S&P 500 from January 29, 2020 through February 25, 2020.
Only our research utilizes the superior data and earnings adjustments featured by the HBS & MIT Sloan paper, “Core Earnings: New Data and Evidence.” The long-term success of our model portfolio strategies highlights the value of our Robo-Analyst technology[1], which scales our forensic accounting expertise (featured in Barron’s) across thousands of stocks[2].
The methodology for this model portfolio mimics an All Cap Blend style with a focus on dividend growth. Selected stocks earn an Attractive or Very Attractive rating, generate positive free cash flow (FCF) and economic earnings, offer a current dividend yield >1%, and have a 5+ year track record of consecutive dividend growth. This model portfolio is designed for investors who are more focused on long-term capital appreciation than current income, but still appreciate the power of dividends, especially growing dividends.
Featured Stock from February: The Allstate Corp ($105/share)
The Allstate Corp is the featured stock from February’s Dividend Growth Stocks Model Portfolio. We first featured Allstate as a Long Idea in June 2015 and closed the position in August 2015. Over that time, the stock was up 3% while the S&P 500 was down 1%.
Since 2015, Allstate has grown revenue by 6% compounded annually and net operating profit after-tax (NOPAT) by 15% compounded annually. Longer-term, Allstate has grown NOPAT by 15% compounded annually over the last decade. The company’s NOPAT margin increased from 6% in 2015 to 9% in 2019 while its ROIC improved from 9% to 15% over the same time.
Figure 1: Allstate’s Revenue & NOPAT Since 2015
Image Source: New Constructs, LLC
Steady Dividend Growth Supported by FCF
Allstate has increased its dividend on common stock in each of the past nine years. The company increased its annualized dividend from $1.20/share in 2015 to $2.00/share in 2019, or 14% compounded annually. Its current quarterly dividend, $0.54/share equates to $2.16/share annually. More importantly, Allstate easily generates the cash flow needed to continue paying and growing its dividend. Over the past five years, Allstate has generated a cumulative $11.5 billion in FCF (33% of market cap) while paying $3.4 billion in dividends.
Companies with FCF well in excess of dividend payments provide higher quality dividend growth opportunities because we know the firm generates the cash to support a higher dividend. On the other hand, the dividend of a company where FCF falls short of the dividend payment over time cannot be trusted to grow or even maintain its dividend because of inadequate free cash flow.
Figure 2: Free Cash Flow (FCF) vs. Regular Dividend Payments
Image Source: New Constructs, LLC
Allstate Is Undervalued
At its current price of $105/share, Allstate has a price-to-economic book value (PEBV) ratio of 0.5. This ratio means the market expects Allstate’s NOPAT to permanently decline by 50% over its remaining corporate life. This expectation seems overly pessimistic for a firm that has grown NOPAT by 2% compounded annually since 1999 and 15% compounded annually over the past decade.
If Allstate can maintain NOPAT margins at its 5-year average of 7% and grow NOPAT by only 2% compounded annually over the next decade, the stock is worth $226/share today – a 115% upside. See the math behind this reverse DCF scenario. Add in Allstate’s 1.8% dividend yield and history of dividend growth, and it’s clear why this stock is in February’s Dividend Growth Stocks Model Portfolio.
Critical Details Found in Financial Filings by Our Robo-Analyst Technology
As investors focus more on fundamental research, research automation technology is needed to analyze all the critical financial details in financial filings as shown in the Harvard Business School and MIT Sloan paper, “Core Earnings: New Data and Evidence”.
Below are specifics on the adjustments we make based on Robo-Analyst findings in The Allstate Corp’s 2019 10-K:
Income Statement: we made $2.3 billion of adjustments with a net effect of removing $812 million in non-operating income (2% of revenue). See all adjustments made to Allstate’s income statement here.
Balance Sheet: we made $5.2 billion of adjustments to calculate invested capital with a net decrease of $555 million. The most notable adjustment was $2.6 billion (10% of reported net assets) in other comprehensive income. See all adjustments to Allstate’s balance sheet here.
Valuation: we made $5.7 billion of adjustments with a net effect of decreasing shareholder value by $5.7 billion. There were no adjustments that increased shareholder value. The most notable adjustment was $2.2 billion in the fair value of preferred stock. This adjustment represents 6% of Allstate’s market value. See all adjustments to Allstate’s valuation here. Despite these subtractions from shareholder value, Allstate remains undervalued.
Disclosure: David Trainer, Kyle Guske II, and Matt Shuler receive no compensation to write about any specific stock, style, or theme.
[1] Harvard Business School features the powerful impact of our research automation technology in the case New Constructs: Disrupting Fundamental Analysis with Robo-Analysts.
[2] This paper compares our analytics on a mega cap company to Bloomberg and Capital IQ (SPGI) in a detailed appendix.
_____
Equities Contributor: David Trainer
Source: Equities News
Read Next
